Advanced search×

Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?

Author(s) unavailable

Ann Intern Med 154(2):I40 (2011) PMID 21135289

DOI: 10.1059/0003-4819-154-2-201101180-00301
Version: za2963e q8za0 q8zb5 q8zce q8zd5 q8zed q8zf5 q8zg2

Similar articles you may find interesting…

  1. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial.
    John B Buse, Richard M Bergenstal, ... Julio Rosenstock

    Ann Intern Med 154(2):103-112 (2010) PMID 21138825

    112 of 138 exenatide recipients and 101 of 123 placebo recipients completed the study. The HbA(1c) level decreased by 1.74% with exenatide and 1.04% with placebo (between-group difference, -0.69% [95% CI, -0.93% to -0.46%]; P < 0.001). Weight decreased by 1.8 kg with exenatide and increased by 1.0...
  2. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type...
    Eric A Schwartz, Juraj Koska, ... Peter D Reaven

    Atherosclerosis 212(1):217-22 (2010) PMID 20557887

    These results demonstrate that exenatide acutely and profoundly inhibits postprandial excursions of proatherogenic lipids and lipoproteins and may offer additional cardiovascular risk reduction (NCT00974272). Published by Elsevier Ireland Ltd....
  3. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type...
    Eric A EA Schwartz, Juraj J Koska, ... Peter D PD Reaven

    Atherosclerosis 212(1):217-22 (2010) PMID 20557887

    These results demonstrate that exenatide acutely and profoundly inhibits postprandial excursions of proatherogenic lipids and lipoproteins and may offer additional cardiovascular risk reduction (NCT00974272). Published by Elsevier Ireland Ltd....